Daniel Francis Donovan, III

FDA Holds Second Transparency Task Force Public Meeting Including Issues Related to Disclosure of Clinical Trial Data
Edward M. Basile, Daniel Francis Donovan, Beverly Lorell, Seth H. Lundy, Jessica Ringel, November 6, 2009
On November 3, the U.S. Food and Drug Administration's (FDA or Agency) Transparency Task Force held its second public meeting. Principal Deputy Commissioner and Task Force leader Joshua Sharfstein stated that the Task Force's goal is to draft recommendations for FDA Commissioner Margaret Hamburg...

Subcommittee on Health Examines Medical Device Safety
Edward M. Basile, Daniel Francis Donovan, Theodore M. Hester, Marian Lee, Beverly Lorell, July 1, 2009
On June 18, 2009, the Subcommittee on Health of the House Committee on Energy and Commerce held a hearing to examine whether the current processes for medical device approval sufficiently protected users of medical devices.

FDA's New Transparency Task Force: Mission and Opportunity for Public Comment
Edward M. Basile, Jennifer L. Bragg, Daniel Francis Donovan, Beverly Lorell, June 26, 2009
On June 3, the U.S. Food and Drug Administration (FDA or Agency) announced the formation of the FDA Transparency Task Force (Task Force) to solicit public comments and to promulgate recommendations for enhancing the transparency of the FDA's internal activities and decision-making.